- Trial Phase
- Phase 2
- Time to Market
- At least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
- Why 8/10
- The next hard, dated catalyst is the 10 mg/kg dose-cohort data readout from the Phase 2 FREEDOM2-DM1 study, expected in November 2026 (~2-3 months away). PGN-EDODM1 is PepGen's lead and only disclosed clinical asset, making this a make-or-break binary event for a nearly single-asset company, warranting an impact score of 8.
Watch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026 — positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.
Price Chart
Executive Summary
PGN-EDODM1 is PepGen Inc.'s lead investigational oligonucleotide therapy for Myotonic Dystrophy Type 1 (DM1), currently in a Phase 2 trial (FREEDOM2-DM1). The drug has FDA Fast Track and Orphan Drug designations but also faces an unresolved partial clinical hold related to preclinical toxicology studies. The next major catalyst is the 10 mg/kg dose-cohort data readout expected in November 2026. PepGen has $117.2M cash (into Q4 2027), a $400M shelf registration creating dilution overhang, and a strongly bullish analyst consensus (12 Buy/Strong Buy, mean PT $10.19 vs. ~$3.11 stock price). RA Capital Management is the largest institutional holder at $36.1M.
How It Works
PGN-EDODM1 is an Enhanced Delivery Oligonucleotide (EDO) therapy — a chemically modified piece of synthetic genetic material designed to correct the underlying RNA splicing defect that causes Myotonic Dystrophy Type 1 (DM1). PepGen's proprietary EDO platform helps deliver the oligonucleotide into muscle and other affected tissues more effectively than earlier-generation antisense therapies.
Trial Status
The FREEDOM2-DM1 Phase 2 study is evaluating PGN-EDODM1 in patients with DM1. The 5 mg/kg cohort has completed with favorable safety and efficacy data. The 10 mg/kg cohort is fully enrolled (7 of 8 participants completed dosing) with data expected November 2026. The DSMB recommended advancing to the highest 12.5 mg/kg dose cohort with no protocol changes and approved OLE dose escalation from 5 mg/kg to 10 mg/kg. No serious adverse events or dose-limiting toxicities have been reported. A separate FREEDOM-OLE open-label extension study has 16 patients enrolled at 5 mg/kg.
The Two-Sided Case
Upcoming Catalysts
- 10 mg/kg dose-cohort data readout from FREEDOM2-DM1 study — expected November 2026
- 12.5 mg/kg highest-dose cohort results — expected 1H 2027
- End-of-Phase 2 meeting with regulators — planned after 12.5 mg/kg data
- Resolution (or not) of the FDA partial clinical hold — no set timeline
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PepGen Inc. 8-K PEPG ·Originating report